Cargando…

Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

BACKGROUND: Viral diversity seems to predict treatment outcomes in certain viral infections. The aim of this study was to evaluate the association between baseline intra-patient viral diversity and hepatitis B surface antigen (HBsAg) decline following PEGylated interferon-alpha (Peg-IFN-α) therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hu, Zhang, Li, Ren, Hong, Hu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939877/
https://www.ncbi.nlm.nih.gov/pubmed/29765238
http://dx.doi.org/10.2147/IDR.S163765
_version_ 1783321018175062016
author Li, Hu
Zhang, Li
Ren, Hong
Hu, Peng
author_facet Li, Hu
Zhang, Li
Ren, Hong
Hu, Peng
author_sort Li, Hu
collection PubMed
description BACKGROUND: Viral diversity seems to predict treatment outcomes in certain viral infections. The aim of this study was to evaluate the association between baseline intra-patient viral diversity and hepatitis B surface antigen (HBsAg) decline following PEGylated interferon-alpha (Peg-IFN-α) therapy. PATIENTS AND METHODS: Twenty-six HBeAg-positive patients who were treated with Peg-IFN-α were enrolled. Nested polymerase chain reaction (PCR), cloning, and sequencing of the hepatitis B virus S gene were performed on baseline samples, and normalized Shannon entropy (Sn) was calculated as a measure of small hepatitis B surface protein (SHBs) diversity. Multiple regression analysis was used to estimate the association between baseline Sn and HBsAg decline. RESULTS: Of the 26 patients enrolled in the study, 65.4% were male and 61.5% were infected with hepatitis B virus genotype B. The median HBsAg level at baseline was 4.5 log(10) IU/mL (interquartile range: 4.1–4.9) and declined to 3.0 log(10) IU/mL (interquartile range: 1.7–3.9) after 48 weeks of Peg-IFN-α treatment. In models adjusted for baseline alanine aminotransferase (ALT) and HBsAg, the adjusted coefficients (95% CI) for ΔHBsAg and relative percentage HBsAg decrease were −1.3 (−2.5, −0.2) log(10) IU/mL for higher SHBs diversity (Sn≥0.58) patients and −26.4% (−50.2%, −2.5%) for lower diversity (Sn<0.58) patients. Further analysis showed that the “a” determinant upstream flanking region and the first loop of the “a” determinant (nucleotides 341–359, 371–389, and 381–399) were the main sources of higher SHBs diversity. CONCLUSION: Baseline intra-patient SHBs diversity was inverse to HBsAg decline in HBeAg-positive chronic hepatitis B (CHB) patients receiving Peg-IFN-α monotherapy. Also, more sequence variations within the “a” determinant upstream flanking region and the first loop of the “a” determinant were the main sources of the higher SHBs diversity.
format Online
Article
Text
id pubmed-5939877
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59398772018-05-14 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B Li, Hu Zhang, Li Ren, Hong Hu, Peng Infect Drug Resist Original Research BACKGROUND: Viral diversity seems to predict treatment outcomes in certain viral infections. The aim of this study was to evaluate the association between baseline intra-patient viral diversity and hepatitis B surface antigen (HBsAg) decline following PEGylated interferon-alpha (Peg-IFN-α) therapy. PATIENTS AND METHODS: Twenty-six HBeAg-positive patients who were treated with Peg-IFN-α were enrolled. Nested polymerase chain reaction (PCR), cloning, and sequencing of the hepatitis B virus S gene were performed on baseline samples, and normalized Shannon entropy (Sn) was calculated as a measure of small hepatitis B surface protein (SHBs) diversity. Multiple regression analysis was used to estimate the association between baseline Sn and HBsAg decline. RESULTS: Of the 26 patients enrolled in the study, 65.4% were male and 61.5% were infected with hepatitis B virus genotype B. The median HBsAg level at baseline was 4.5 log(10) IU/mL (interquartile range: 4.1–4.9) and declined to 3.0 log(10) IU/mL (interquartile range: 1.7–3.9) after 48 weeks of Peg-IFN-α treatment. In models adjusted for baseline alanine aminotransferase (ALT) and HBsAg, the adjusted coefficients (95% CI) for ΔHBsAg and relative percentage HBsAg decrease were −1.3 (−2.5, −0.2) log(10) IU/mL for higher SHBs diversity (Sn≥0.58) patients and −26.4% (−50.2%, −2.5%) for lower diversity (Sn<0.58) patients. Further analysis showed that the “a” determinant upstream flanking region and the first loop of the “a” determinant (nucleotides 341–359, 371–389, and 381–399) were the main sources of higher SHBs diversity. CONCLUSION: Baseline intra-patient SHBs diversity was inverse to HBsAg decline in HBeAg-positive chronic hepatitis B (CHB) patients receiving Peg-IFN-α monotherapy. Also, more sequence variations within the “a” determinant upstream flanking region and the first loop of the “a” determinant were the main sources of the higher SHBs diversity. Dove Medical Press 2018-05-03 /pmc/articles/PMC5939877/ /pubmed/29765238 http://dx.doi.org/10.2147/IDR.S163765 Text en © 2018 Li et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Li, Hu
Zhang, Li
Ren, Hong
Hu, Peng
Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
title Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
title_full Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
title_fullStr Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
title_full_unstemmed Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
title_short Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
title_sort higher baseline viral diversity correlates with lower hbsag decline following pegylated interferon-alpha therapy in patients with hbeag-positive chronic hepatitis b
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939877/
https://www.ncbi.nlm.nih.gov/pubmed/29765238
http://dx.doi.org/10.2147/IDR.S163765
work_keys_str_mv AT lihu higherbaselineviraldiversitycorrelateswithlowerhbsagdeclinefollowingpegylatedinterferonalphatherapyinpatientswithhbeagpositivechronichepatitisb
AT zhangli higherbaselineviraldiversitycorrelateswithlowerhbsagdeclinefollowingpegylatedinterferonalphatherapyinpatientswithhbeagpositivechronichepatitisb
AT renhong higherbaselineviraldiversitycorrelateswithlowerhbsagdeclinefollowingpegylatedinterferonalphatherapyinpatientswithhbeagpositivechronichepatitisb
AT hupeng higherbaselineviraldiversitycorrelateswithlowerhbsagdeclinefollowingpegylatedinterferonalphatherapyinpatientswithhbeagpositivechronichepatitisb